The lowest effective intensity of prophylactic anticoagulation for patients with atrial fibrillation

Cerebrovascular Diseases

Volumn 20, Issue 2, 2005, Pages 114-119

  Cheung, Chun Ming ^a   Tsoi, Tak Hong ^a   Huang, Chen Ya ^b  

^a PAMELA YOUDE NETHERSOLE EASTERN HOSPITAL   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Anticoagulation; Atrial fibrillation; Stroke prevention

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; DRUG INDICATION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART VALVE PROSTHESIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; PATIENT SELECTION; PRIORITY JOURNAL; PROPHYLAXIS; STROKE; SUDDEN DEATH; THROMBOEMBOLISM; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; CHINA; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; WARFARIN;

EID: 23844479021     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086801     Document Type: Article

References (21)

1. Segal JB, McNamara RC, Miller MR, Powe NR, Goodman SN, Robinson KA, Bass EB: Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter. Cochrane Database Syst Rev 2002;1:CD001938.
2. Hart R: Stroke prevention in patients with nonvalvular AF. Neurology 1998;51:671-673.
3. Guo GB, Chang HW, Chen MC, Yang CH: Underutilization of anticoagulation therapy in chronic atrial fibrillation. Jpn Heart J 2001;42:55-65.
4. Mendelson G, Aronow WS: Underutilization of warfarin in older persons with chronic non-valvular atrial fibrillation at high risk for developing stroke. J Am Geriatr Soc 1998;46:1423-1425.
5. Hack W, Kaste M, Bogousslavsky J, Brainin M, Chamorro A, Lees K, Leys D, Kwiecinski H, Toni P, Langhorne P, Diener C, Hennerici M, Ferro J, Sivenius J, Gunnar N, Bath P, Olsen TS, Gugging M, European Stroke Initiative Executive Committee and the EUSI Writing Committee: European Stroke Initiative recommendations for stroke management - Update 2003. Cerebrovasc Dis 2003;16:311-337.
6. Mok V, Wong KS, Lam WWM, Poon WS, Kay R: Warfarin associated intracerebral hemorrhage occurs with lower intensification of anticoagulation in Chinese. Neurol J Southeast Asia 2001;6:107-111.
7. Fuster V, Ryden LE, et al: ACC/AHA/ESC practice guidelines - Executive summary. J Am Coll Cardiol 2001;38:1231-1266.
8. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJM, Vandenbrouche JP, Briet E: Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995;333:11-17.
9. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group: Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: a multicenter, prospective, randomised trial. Stroke 2000;31:817-821.
10. White RH, Beyth RJ, Zhou H, Romano PS: Major bleeding after hospitalization for deep-venous thrombosis. Am J Med 1999;107:414-424.
11. White RH, Zhou H, Romano PS: Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med 1998;128:737-740.
12. Sun X, Hu S, Qi G, Zhou Y: Low standard oral anticoagulation therapy for Chinese patients with St. Jude mechanical heart valves. Chin Med J (Engl) 2003;116:1175-1178.
13. Petersen P, Boysen G, Godtfredsent J, Andersen ED, Andersen B: Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet 1989;i:175-179.
14. The European Atrial Fibrillation Trial Study Group: Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-1262.
15. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators: The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505-1511.
16. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, Krause-Steinrauf H, Kurtzke JF, Nazarian SM, Radford MJ, Rickles FR, Shabetai R, Deykin D, for the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators: Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992;327:1406-1457.
17. Stroke Prevention in Atrial Fibrillation Investigators: Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994;343:687-691.
18. Van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briet E: Bleeding complications in oral anticoagulant therapy - An analysis of risk factors. Arch Intern Med 1993;153:1557-1562.
19. The European Atrial Fibrillation Trial Study Group: Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischaemia. N Engl J Med 1995;333:5-10.
20. Pengo V, Barbero F, Biasiolo A, Pegoraro C, Noventa F, Iliceto S: Prevention of thromboembolism in patients with mitral stenosis and associated atrial fibrillation: effectiveness of low intensity (INR target 2) oral anticoagulant treatment. Thromb Haemost 2003;89:760-764.
21. Hylek EM, Go AS, Chang Y, Jensvold NG, Renault LE, Selby JV, Singer DE: Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003;349:1019-1026.